145 related articles for article (PubMed ID: 16332596)
1. The potential of proton beam radiation therapy in lung cancer (including mesothelioma).
Bjelkengren G; Glimelius B
Acta Oncol; 2005; 44(8):881-3. PubMed ID: 16332596
[TBL] [Abstract][Full Text] [Related]
2. The potential of proton beam radiation therapy in head and neck cancer.
Ask A; Björk-Eriksson T; Zackrisson B; Blomquist E; Glimelius B
Acta Oncol; 2005; 44(8):876-80. PubMed ID: 16332595
[TBL] [Abstract][Full Text] [Related]
3. The potential of proton beam radiation therapy in breast cancer.
Björk-Eriksson T; Glimelius B
Acta Oncol; 2005; 44(8):884-9. PubMed ID: 16332597
[TBL] [Abstract][Full Text] [Related]
4. The potential of proton beam therapy in paediatric cancer.
Björk-Eriksson T; Glimelius B
Acta Oncol; 2005; 44(8):871-5. PubMed ID: 16332594
[TBL] [Abstract][Full Text] [Related]
5. The potential of proton beam radiation therapy in gastrointestinal cancer.
Ask A; Johansson B; Glimelius B
Acta Oncol; 2005; 44(8):896-903. PubMed ID: 16332599
[TBL] [Abstract][Full Text] [Related]
6. The potential of proton beam radiation for palliation and reirradiation.
Björk-Eriksson T; Ask A; Glimelius B
Acta Oncol; 2005; 44(8):918-20. PubMed ID: 16332602
[TBL] [Abstract][Full Text] [Related]
7. The potential of proton beam radiation therapy in prostate cancer, other urological cancers and gynaecological cancers.
Johansson B; Ridderheim M; Glimelius B
Acta Oncol; 2005; 44(8):890-5. PubMed ID: 16332598
[TBL] [Abstract][Full Text] [Related]
8. The potentials of proton beam radiation therapy in malignant lymphoma, thymoma and sarcoma.
Björk-Eriksson T; Bjelkengren G; Glimelius B
Acta Oncol; 2005; 44(8):913-7. PubMed ID: 16332601
[TBL] [Abstract][Full Text] [Related]
9. Number of patients potentially eligible for proton therapy.
Glimelius B; Ask A; Bjelkengren G; Björk-Eriksson T; Blomquist E; Johansson B; Karlsson M; Zackrisson B
Acta Oncol; 2005; 44(8):836-49. PubMed ID: 16332591
[TBL] [Abstract][Full Text] [Related]
10. The potential of proton beam radiation therapy in intracranial and ocular tumours.
Blomquist E; Bjelkengren G; Glimelius B
Acta Oncol; 2005; 44(8):862-70. PubMed ID: 16332593
[TBL] [Abstract][Full Text] [Related]
11. Uncertainty reduction in intensity modulated proton therapy by inverse Monte Carlo treatment planning.
Morávek Z; Rickhey M; Hartmann M; Bogner L
Phys Med Biol; 2009 Aug; 54(15):4803-19. PubMed ID: 19622848
[TBL] [Abstract][Full Text] [Related]
12. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.
Suit H; Kooy H; Trofimov A; Farr J; Munzenrider J; DeLaney T; Loeffler J; Clasie B; Safai S; Paganetti H
Radiother Oncol; 2008 Feb; 86(2):148-53. PubMed ID: 18237800
[TBL] [Abstract][Full Text] [Related]
13. Clinical implementation of full Monte Carlo dose calculation in proton beam therapy.
Paganetti H; Jiang H; Parodi K; Slopsema R; Engelsman M
Phys Med Biol; 2008 Sep; 53(17):4825-53. PubMed ID: 18701772
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study.
Hata M; Tokuuye K; Kagei K; Sugahara S; Nakayama H; Fukumitsu N; Hashimoto T; Mizumoto M; Ohara K; Akine Y
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):786-93. PubMed ID: 17379439
[TBL] [Abstract][Full Text] [Related]
15. Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysis.
Macdonald OK; Kruse JJ; Miller JM; Garces YI; Brown PD; Miller RC; Foote RL
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):950-8. PubMed ID: 19801106
[TBL] [Abstract][Full Text] [Related]
16. SBRT of lung tumours: Monte Carlo simulation with PENELOPE of dose distributions including respiratory motion and comparison with different treatment planning systems.
Panettieri V; Wennberg B; Gagliardi G; Duch MA; Ginjaume M; Lax I
Phys Med Biol; 2007 Jul; 52(14):4265-81. PubMed ID: 17664607
[TBL] [Abstract][Full Text] [Related]
17. Treatment plan comparison between helical tomotherapy and MLC-based IMRT using radiobiological measures.
Mavroidis P; Ferreira BC; Shi C; Lind BK; Papanikolaou N
Phys Med Biol; 2007 Jul; 52(13):3817-36. PubMed ID: 17664579
[TBL] [Abstract][Full Text] [Related]
18. Dosimetric advantages of IMPT over IMRT for laser-accelerated proton beams.
Luo W; Li J; Fourkal E; Fan J; Xu X; Chen Z; Jin L; Price R; Ma CM
Phys Med Biol; 2008 Dec; 53(24):7151-66. PubMed ID: 19033641
[TBL] [Abstract][Full Text] [Related]
19. A review of the impact of photon and proton external beam radiotherapy treatment modalities on the dose distribution in field and out-of-field; implications for the long-term morbidity of cancer survivors.
Palm A; Johansson KA
Acta Oncol; 2007; 46(4):462-73. PubMed ID: 17497313
[TBL] [Abstract][Full Text] [Related]
20. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer.
Chang JY; Zhang X; Wang X; Kang Y; Riley B; Bilton S; Mohan R; Komaki R; Cox JD
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1087-96. PubMed ID: 16682145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
